DANA ALBRECHT: Open Payments
NPI 1043773815 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$498 in 27 payments from 9 companies in 2025. Trend: 2023 $812 · 2024 $811 · 2025 $498
Food & beverage: $498
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $140 |
| Lilly USA, LLC | 5 | $76 |
| Edwards Lifesciences Corporation | 1 | $72 |
| ABBVIE INC. | 4 | $68 |
| Novo Nordisk Inc | 3 | $65 |
| GlaxoSmithKline, LLC. | 2 | $28 |
| Abbott Laboratories | 1 | $18 |
| Amgen Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
Products named: MOUNJARO, SAPIEN 3 Ultra RESILIA, AIRSUPRA, UBRELVY, BREZTRI, FARXIGA, SHINGRIX, Wegovy.
Industry payments across MS — which companies pay providers there.
